Managing breast cancers with low estrogen receptor and HER2 by drugging both

Clin Cancer Res. 2014 Feb 1;20(3):528-30. doi: 10.1158/1078-0432.CCR-13-2994. Epub 2013 Dec 18.

Abstract

Low estrogen receptor (ER) levels in breast tumors are associated with poorer response to antiestrogen therapy. Finn and colleagues identify low ER levels as a biomarker predicting benefit from the addition of the EGFR/HER2 dual inhibitor lapatinib to an antiestrogen treatment regimen in patients with metastatic ER(+)/HER2(-) breast cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / metabolism*
  • Female
  • Humans
  • Lapatinib
  • Quinazolines / administration & dosage*
  • Receptors, Estrogen / biosynthesis*
  • Receptors, Progesterone / biosynthesis*

Substances

  • Quinazolines
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Lapatinib